BOCA RATON, Fla, Jan. 09, 2023 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce the following promotions and appointments to its management team:
Maggie Martinez has been promoted to Chief Operating Officer
Emiliano Sosa has been promoted to Chief Technical Officer
Stephanie Tipton has been promoted to Vice President of Marketing
Sean Delaney has been appointed Vice President of Regulatory and Quality Assurance
Wayne Lura has been appointed Vice President of Aesthetic Sales
Ms. Martinez joined Sensus nine years ago and subsequently held positions of increasing responsibility. Most recently she served as Vice President of Operations, and in her new role as COO she will be responsible for all aspects of customer support and satisfaction, vendor relations, intra-company communication and processes. Ms. Martinez holds a B. S. degree in marketing from Stetson University in DeLand, Florida.
Mr. Sosa joined Sensus last year as Vice President of Technology Development with extensive experience in banking, cyber security and artificial intelligence. Among his accomplishments are the introduction and engineering of the first GPS device in the Argentina market with real time streaming video cameras for vehicles (founding Overmax S.A.). His company in the U.S. was recognized as 2016 small business of the year. He has also designed and developed electroencephalography and brain mapping devices, implementing the first 3-D EEG Brain Mapping medical devices and polysomnographs at the time. In his new position he is charged with overseeing and expanding the company’s team of engineers to provide dependable and differentiated technologies to customers and their patients. A priority focus will be on expanding the capabilities and indications of the company’s Sentinel™ technology. Sentinel provides asset management and HIPAA-compliant patient data and storage capability, and also contains the software necessary to support shared service models including direct patient billing. Mr. Sosa holds degrees in information systems engineering from the National University of Technology in Buenos Aires, and in international marketing and foreign trade from the University of Buenos Aires in Argentina.
Ms. Tipton joined Sensus in June of 2021 as the Director of Digital Marketing, revamping the company’s social media and on-line outreach, which resulted in a dramatic increase in patient and physician inquiries. She has also worked closely with the company’s clinical, sales, and engineering teams to provide a more comprehensive approach to the product portfolio. As an experienced marketing professional with a record of success, she was President of Tipton Group, a marketing consulting firm prior to joining Sensus. Previously she was for six years Industrial Director/Director of Sales for Nova Medical Centers in Knoxville, Tenn. Ms. Tipton holds a B.S. degree in biology and business administration from the University of Tennessee, Knoxville.
Mr. Delany brings to Sensus nearly 20 years of product development experience in regulatory affairs, quality assurance and regulatory compliance, including worldwide regulatory clearances and approvals, development and product quality, international standard compliance and post–market surveillance. Much of his experience is in software-controlled image-guided radiation therapy systems. Most recently, Mr. Delaney worked at ViewRay, with responsibility for regulatory affairs and compliance, quality assurance, radiation safety and U.S. Food and Drug Administration submissions. He holds a B.S. in physics from San Jose State University and an MBA from Santa Clara University, Leavey School of Business.
Mr. Lura has two decades of experience in medical aesthetics, bringing new products to market at such notable companies as Cynosure, Eclipse Medical, DefenAge Skincare, Zimmer Medical Systems, Cutera, and Lumenis. He will be responsible for expanding Sensus’ aesthetics footprint as the company continues to add to its product portfolio, and developing opportunities for product introductions including developing a total solution bundle for Sensus customers. Mr. Lura brings to Sensus deep relationships with industry KOLs and dermatologists. He holds a B.A. in communications from Concordia University Texas, attended the United States Airforce Academy and was a commissioned Second Lieutenant in the Air Force ROTC at the University of Texas, Austin.
“Our history of growth, execution and expanding market opportunities have made these staff changes both necessary and prudent, including creating several new positions. I am delighted to announce these promotions and appointments and look forward to the contributions of these talented individuals as Sensus executes on an aggressive business strategy,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “Maggie Martinez has proven over and over again her initiative, drive and commitment to the company, our customers and patients and I am proud of her appointment to Chief Operating Officer. In just a short period of time, Emiliano Sosa has distinguished himself in assembling a high-quality team of engineers who are adding exceptional value to our technologies. His leadership skills and technical acumen ideally qualify him to serve as our Chief Technical Officer. Stephanie Tipton has been a creative force in digital marketing for the company, and going forward she is charged with assuming a leadership role in all aspects of marketing. She will be instrumental in supporting the introduction of new products to the marketplace, an important initiative for Sensus.”
Mr. Sardano added, “Our anticipated growth has necessitated the expansion of our senior management team. I’m thrilled Sean Delany has joined Sensus as Vice President of Regulatory and Quality Assurance. Sean comes to us with deep experience navigating regulatory pathways not only in the U.S., but in all of Asia, the EU and South America. His knowledge will be valuable as we work to secure regulatory clearances for our products – both existing and new – around the world. Additionally, we look forward to even greater success with our growing aesthetics product portfolio with Wayne Lura at the helm. His appointment underscores our plans to expand our aesthetic footprint with innovative products. Wayne has a wealth of contacts and enjoys excellent relationships with the leaders in aesthetic medicine.
“Our goal is for Sensus to be a destination for great employees from all walks of life and backgrounds. I am proud of our diverse and talented workforce, all contributing to our success with an unwavering commitment to quality, innovation, teamwork, respect and customer service,” Mr. Sardano concluded.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are or may be deemed ”forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: the continuation and severity of the COVID-19 pandemic, including its impact on sales and marketing; our ability to achieve profitability; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. In addition, we note that our revenues and profits for the year ended December 31, 2022 are subject to adjustments, including adjustments that may be made in connection with the completion of our audited financial statements.
At the present time, we do not expect that the Russia-Ukraine conflict and global geopolitical uncertainty will have any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the “Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
Related Quotes
Arhaus Inc (NASDAQ: ARHS) has raised its full-year 2022 revenue guidance from $1.173 billion – $1.193 billion to $1.223 billion – $1.228 billion versus the $1.19 billion consensus. It also raised FY22 comparable growth forecast from 43% – 48% to 51.0% – 51.4%. The company sees fourth-quarter FY22 revenue of $351 million – $356 million versus $312.74 million. The company reported Q3 revenue of $320 million and comparable growth of 54.3%. "We are encouraged by the outstanding performance and conti
Voyager Therapeutics Inc., the gene therapy startup led by erstwhile Biogen Inc. executive Al Sandrock, has a new deal with a San Diego biotech that's worth up to $4.2 billion.
Yahoo Finance Live anchors discuss the rise in stock for Bed Bath & Beyond following third-quarter earnings.
After the bear market of 2022 slammed the share prices of most companies, now is a particularly opportune time to identify passive income stocks while they're cheap. With that in mind, let's investigate three stocks that could help you shore up your passive income streams. Pharma company AbbVie (NYSE: ABBV) is a screaming buy because of its proven ability to keep commercializing new medicines year after year.
Major market indexes gave up early gains on Monday, and Wall Street looks ready for a lower open on Tuesday morning based on stock index futures. Several stocks made big moves Tuesday morning on news related to mergers and acquisitions. For Oak Street Health (NYSE: OSH), speculation about a potential acquisition by a healthcare giant gave the stock a big boost.
‘Should we be redecorating, going to Cancun and Disney World and getting takeout every night instead?’
Macroeconomic challenges have reshaped the way the market is thinking about growth stocks. Cloudflare (NYSE: NET) is the world's leading provider of protection against distributed-denial-of-service (DDoS) attacks. The company ended the third quarter with 1,908 customers generating more than $100,000 in annualized sales, up from 451 in the third quarter of 2019 and good for a compound annual growth rate of 61% over the last two years.
According to the average brokerage recommendation (ABR), one should invest in Plug Power (PLUG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
The outlook for stocks in 2023 is still in flux. Last year’s headwinds haven’t dissipated, so we’ll be dealing with high inflation, rising interest rates, the Russia-Ukraine war, and an increased risk of recession for the foreseeable future, and that has investors taking an interest in defensive plays. The classic move, of course, is to move heavily into dividend stocks. These bring several advantages that can protect an investment portfolio during an unsettled economic period, including a relia
We are yet to find out what lies in store for the stock market in 2023. However, we do know that the previous year was one of the worst ever, with the S&P 500 putting in its 7th most abject annual performance since 1929. Whichever way you look at it, then, most investors did not enjoy the past 12 months’ market action. One positive takeaway, however, is that the overall bearish trend has driven share prices down across the board and that has left some stocks at levels that are now just too cheap
Since Warren Buffett purchased a controlling stake in Berkshire Hathaway in 1965 and made it the foundation for his investing empire, the stock has seen staggering gains of more than 2,677,400%. While Berkshire's market capitalization of roughly $703 billion and status as the world's sixth largest publicly traded company means that its most explosive growth is almost surely in the past, the Oracle of Omaha's company remains one of the best-run investment conglomerates on the planet, and it's absolutely trounced the S&P 500 index across the past year of trading. Snowflake (NYSE: SNOW) might not be a great fit for every investor.
Recently, Zacks.com users have been paying close attention to Enphase Energy (ENPH). This makes it worthwhile to examine what the stock has in store.
Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) has one of the most closely followed stock portfolios in the world. The conglomerate owns about four dozen stocks, with a combined market value of more than $325 billion, and many of the positions were chosen by legendary investor Warren Buffett himself. Here's what they are, and why they're my favorite "Buffett stocks" for the long term.
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will…
The shares of the producer of fuel cell systems for on-site power generation could go higher but the technical evidence isn't convincing at this stage.
It's the underlying businesses that fund their dividends that make these stocks especially attractive.
Palantir (NYSE: PLTR) and Salesforce (NYSE: CRM) both own cloud-based platforms that gather and analyze large amounts of data to help their clients make smarter decisions. Analysts expect Salesforce to generate $31 billion in revenue in its fiscal 2023 year (which ends this month), or more than 16 times the $1.9 billion in revenue Palantir was expected to generate in 2022. Let's review Palantir's approach to data mining, how much larger it could grow, and if it could evolve into a blue-chip cloud giant like Salesforce in the future.
As of 2:45 p.m. ET, RIOT stock has rocketed 15.4%, among the leaders in the tech-heavy Nasdaq. The price of Bitcoin (CRYPTO: BTC) has continued to move higher, appreciating 2.3% over the past 24 hours. For Bitcoin miners such as Riot, this is a key fundamental metric, which is typically the directional driver for price movements on a given day.
With the Nasdaq Composite falling 33% in the year, it might have seemed like every time you bought a stock, it fell 20%, 30%, or more in the following weeks. For reference, if you invested $10,000 in the Nasdaq Composite at the beginning of 2009, you would have over $65,300 today — even after the drop in 2022. Shares of Datadog (NASDAQ: DDOG) got crushed in 2022, falling nearly 59%.
What happened Shares of Novocure (NASDAQ: NVCR) are sinking today, down by 15.4% as of 10:44 a.m. ET. The decline came after the company announced its preliminary full-year and fourth-quarter 2022 net revenue numbers.